Idiopathic Inflammatory Myopathies
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
31564297
DOI
10.1016/j.rdc.2019.07.006
PII: S0889-857X(19)30061-4
Knihovny.cz E-resources
- Keywords
- Autoantibodies, Criteria, Exercise, Myositis, Target, Treatment,
- MeSH
- Antirheumatic Agents pharmacology MeSH
- Autoantibodies analysis MeSH
- Humans MeSH
- Patient Care Management methods MeSH
- Myositis * diagnosis immunology therapy MeSH
- Severity of Illness Index MeSH
- Symptom Assessment methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- Autoantibodies MeSH
Major advances have been made in the field of idiopathic inflammatory myopathies (IIM), or myositis, that are likely to facilitate development of new therapeutic strategies that have not yet been applied in this group of diseases. These advances include new classification criteria to better identify the patients with IIM, detection of several new myositis-specific autoantibodies that facilitates subgrouping of patients into more specific clinical phenotypes, development of outcome measures for disease activity, and new response criteria. We have learned from clinical studies that exercise is an important part of treatment and that pharmacologic treatment should be combined with exercise.
References provided by Crossref.org
Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study